Jamie Bacher on the One Obstacle Synthetic Biology Must Finally Solve

Mohamed Soufi

Apr 3, 2026

In an exclusive conversation ahead of his panel appearance at SynBioBeta in May, biomanufacturing veteran Jamie Bacher is blunt about what’s holding synthetic biology back: time to market.

Bacher's newest company, Finish Line Bio, is built around that urgency. "My newest company is focused on helping biomanufacturing companies reach economic cost of goods on a timeframe that makes sense," he says. The vision is an AI-ready database that tells strain engineers exactly which genetic changes to make, especially non-obvious changes.

When fully developed, Finish Line Bio expects to be able to design strains for high yield in minutes, enabling one researcher (or robot) to engineer and validate them in months rather than years. "It’s a great ROI," Bacher continues. "Our approach will identify novel opportunities to optimize strains for specific applications without long, risky, and expensive development projects for customers." The pitch is simple and customers get it. The company has already secured several letters of intent to prove it.

Bacher has a blend of successes and hard-earned lessons that now shape his perspectives. He started in industry during the biofuels era. Successes in strain directed evolution in algal biofuels led his teams to hit major funding and technical milestones. That experience set him up for his role as deputy director of a $100 million partnership between Amyris and Total New Energies, with a view into the full range of discovery, development, and manufacturing. In these roles, he was hands-on and saw close-up the challenges of strain engineering, as well as the application of all sorts of strategies to access the unpredictable genetic changes. It was often these unpredictable genetics that could dramatically change production levels and move strain improvement projects off plateaus of strain development.

“How do we take advantage of the unknown-unknowns to optimize genomes?” he asks. While strain engineers are very capable at addressing the known challenges of strain improvement – such as optimizing expression levels to increasing flux through pathways, preventing carbon flux along alternative pathways, balancing redox – the unknown-unknowns are addressed through methods that are much more challenging. Random mutagenesis followed by screening is the classic approach. More recent years have focused on developing biosensors to link production of specific molecules to growth or selectable or screenable markers. These approaches are labor intensive, unpredictable or hard to implement, and expensive both in time and money.

Bacher has been on his entrepreneurial journey for over a decade. He launched his first startup at SynBioBeta #2 in 2013; and later started a second company that developed a crop protection product that is now on the market. He raised venture capital and closed partnerships and licensing agreements with multi-billion-dollar market cap companies. Across these experiences, he saw first-hand the full range of technical, market, regulatory, and scale-up challenges that shape the biomanufacturing industry today. He’s earned the right to be skeptical. “The industry has made incredible progress in this over the last couple of decades, but there have been many more failures than successes in the space, with time to market-competitive cost of goods as one of the primary challenges.”

When asked what perspective founders most often lack, he doesn’t hesitate. “The core lesson is understanding the path to market,” Bacher says. “What are the timelines for all the steps that have to happen for a technology to be market-ready, especially pricing, but also factors like the regulatory path and distribution channels?” He continues, that the time to reach market-competitive cost of goods has been the killer – with many companies not lasting long enough to reach competitive production costs, and many more that didn’t have the technology to reach that point.

He also believes the field needs to move away from the idea of a single silver bullet. When it comes to commodity or near-commodity chemical products, he says it is likely that distinct technologies will need to come together before biomanufacturing becomes cost-effective, more than just novel approaches to strain engineering that can directly lower production costs. It demands novel approaches for process development and downstream processing. However, he emphasizes that addressing problems via strain development is much cheaper than addressing them as part of process-oriented approaches. “You can spend an incremental $200K on your strain, $2M on process development, or $200M on your manufacturing facility; if we can create value with the hard-to-find genetic opportunities Finish Line can identify, I know which one I’d choose.”

This perspective is not new for Bacher. Back in 2014, he wrote “5 Considerations for Synthetic Biology Investors” for SynBioBeta 1. While some of the article now seems dated, key points around teams and the path to commercialization remain central to success today. His core message remains unchanged: companies rarely fail because the biology is impossible; they fail because the economics do not work.

Beyond cost curves, “the other area I’m cheering on is biology that can have a real impact on climate,” he says. “I’m looking forward to seeing how syn bio folks figure out how to have a gigaton-scale impact. There are companies developing exciting technologies; I look forward to following their successes.”

For SynBioBeta 2026 attendees, his message is both a warning and a call to action. There is a “desperate need for innovation that can directly impact the time to competitive cost of goods in biomanufacturing,” he says, adding, “I hope the audience leaves with inspiration to learn more about new technologies to directly address time and cost of getting to market.”

If they do, the next generation of biomanufacturing companies may finally be recognized for delivering economically viable solutions on a world-changing scale.